Peer-reviewed veterinary case report
How prednisone affects blood thinning by rivaroxaban in healthy dogs
By Hafner, Paige M et al.Ā·Published in Journal of veterinary internal medicineĀ·2022Ā·Department of Clinical Sciences, United StatesĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs.
- Species:
- dog
Plain-English summary
A study involving nine healthy dogs tested the effects of rivaroxaban, a blood thinner, and prednisone, a steroid, to see if they impacted each other's effectiveness. The dogs were given either rivaroxaban, prednisone, or both, and their blood clotting times were measured over several days. The results showed that prednisone did not change how well rivaroxaban worked, meaning that if your dog needs both medications, the dosages likely won't need to be adjusted. This finding is helpful for veterinarians when treating dogs that require both treatments.
People also search for: dog blood thinner rivaroxaban Ā· prednisone for dogs Ā· dog medication interactions
Abstract
BACKGROUND: The potential effects of glucocorticoid administration on rivaroxaban's anticoagulant bioactivity in dogs, and an appropriate rivaroxaban dosage regimen for dogs receiving glucocorticoid therapy are unknown. HYPOTHESIS/OBJECTIVES: The objective was to determine whether glucocorticoid administration influences the anticoagulant effects of rivaroxaban in healthy dogs. We hypothesized that administration of rivaroxaban and prednisone would reduce the anticoagulant intensity compared with rivaroxaban alone. ANIMALS: Nine healthy dogs. METHODS: Randomized, cross-over study. Dogs were administered prednisone (2 mg/kg, PO, q24h), rivaroxaban (1.5 mg/kg, PO, q24h), or prednisone and rivaroxaban, and the coagulation status was evaluated using prothrombin time (PT), and rivaroxaban-calibrated anti-Xa activity (RIVA, results were logtransformed for analysis), before drug administration and on days 2, 4, and 8. Linear mixed models and correlation were used to evaluate associations in variables (P < .05 was considered significant). RESULTS: There were no differences in RIVA results for the rivaroxaban and prednisone/rivaroxaban groups on day 8 (P = .599, median 87 [range 45-156] to 167 [56-333], respectively, median difference 90 ng/mL [95% CI:87.3-161.8]) There was a strong correlation between RIVA and PT results when days 2, 4, and 8 were combined (r = .846, P < .001), and increased during drug administration, day 2 (r = .810, P < .001), day 4 (r = .863, P < .001), and day 8 (r = .885, P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Clotting times in the PT correlate with rivaroxaban levels and may prove useful for drug monitoring. Prednisone administration had no apparent influence on the anticoagulant effects of rivaroxaban in healthy dogs, suggesting that combined therapy will not require dosage adjustments.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36399000/